Warning letter
Raphah, Inc.: warning letter of Feb 26, 2016
FDA warning letter 481817 · New Jersey District Office
Key facts
| Reference number | 481817 |
|---|---|
| Company | Raphah, Inc. |
| Subject | CGMP/Dietary Supplement/Adulterated |
| Issue date | Feb 26, 2016 |
| Posted date | Mar 8, 2016 |
| Issuing office | New Jersey District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 111.260(l)(1)(i), 111, 111.73, 111.103, 111.210, 111.453, 111.25(a), 111.35(b)(1), 111.70(a), 111.70(b), 111.70(b)(1), 111.70(d) and 22 more |
| Inspection city | New Brunswick |
| Inspection ZIP | 08901 |
| Inspection start date | Sep 17, 2015 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: